title: Emollient for maintenance therapy after topical corticotherapy in mild psoriasis.
abstract: Emollients or moisturizers can act as an important adjunctive therapy of topical treatment in psoriatic patients. However, the interest of emollients has never been clearly demonstrated; i.e. are they able to improve topical treatment efficacy and/or maintain continuous remission of the disease? The aim of this study was to evaluate the effect of an emollient on patients with mild plaque psoriasis during and after standard local corticosteroid therapy. Results showed that the use of an emollient can limit relapses after the end of corticotherapy, and maintain the improvement obtained after 1 month corticotherapy at clinical level (physician global assessment) and skin dryness.
authors.affiliation: La Roche-Posay Pharmaceutical Laboratories, 110 Avenue Henri Barbusse, 92602 Asnières Cedex, France. sseite@dca.loreal.com
authors.forename: S
authors.initials: S
authors.lastname: Seité
authors.forename: A
authors.initials: A
authors.lastname: Khemis
authors.forename: A
authors.initials: A
authors.lastname: Rougier
authors.forename: J P
authors.initials: JP
authors.lastname: Ortonne
mesh_terms: D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004643:Emollients / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D055502:Secondary Prevention; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D004643:Emollients